What is William Blair’s Estimate for AbbVie FY2027 Earnings?

AbbVie Inc. (NYSE:ABBV) – Investment analysts at William Blair upped their FY2027 earnings per share estimates for shares of AbbVie in a research report issued on Thursday, September 11th. William Blair analyst M. Phipps now expects that the company will post earnings per share of $16.14 for the year, up from their previous estimate of $16.11. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

ABBV has been the topic of several other research reports. Morgan Stanley raised their price target on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Citigroup lifted their target price on AbbVie to $205.00 and gave the company a “hold” rating in a research note on Wednesday, June 11th. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price on the stock in a research note on Thursday, August 7th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Bank of America lifted their target price on AbbVie to $204.00 and gave the company a “hold” rating in a research note on Monday, June 9th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $217.10.

AbbVie Trading Down 0.8%

Shares of NYSE ABBV opened at $218.40 on Friday. The company has a market cap of $385.82 billion, a price-to-earnings ratio of 104.00, a price-to-earnings-growth ratio of 1.42 and a beta of 0.53. AbbVie has a 12-month low of $163.81 and a 12-month high of $221.76. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The stock’s 50 day simple moving average is $200.25 and its 200 day simple moving average is $194.58.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.24 by ($0.27). The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.65 EPS.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be issued a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Wednesday, October 15th. AbbVie’s payout ratio is presently 312.38%.

Insiders Place Their Bets

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the second quarter valued at $25,000. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter valued at $26,000. TD Capital Management LLC grew its holdings in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at $28,000. Finally, Abound Financial LLC purchased a new position in shares of AbbVie during the first quarter valued at $30,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.